Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
In the preceding three months, 4 analysts have released ratings for Pediatrix Medical Group (NYSE:MD), presenting a wide array of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 0 | 0 | 4 | 0 | 0 |
Last 30D | 0 | 0 | 1 | 0 | 0 |
1M Ago | 0 | 0 | 0 | 0 | 0 |
2M Ago | 0 | 0 | 0 | 0 | 0 |
3M Ago | 0 | 0 | 3 | 0 | 0 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $9.5, a high estimate of $10.00, and a low estimate of $9.00. This current average has decreased by 6.13% from the previous average price target of $10.12.
The perception of Pediatrix Medical Group by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
---|---|---|---|---|---|
David Macdonald | Truist Securities | Maintains | Hold | $10.00 | $10.00 |
Brian Tanquilut | Jefferies | Lowers | Hold | $9.00 | $10.00 |
Ann Hynes | Mizuho | Lowers | Neutral | $9.00 | $10.00 |
David Macdonald | Truist Securities | Lowers | Hold | $10.00 | $10.50 |
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Pediatrix Medical Group's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on Pediatrix Medical Group analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Pediatrix Medical Group Inc provides physician services to hospitals, intensive care units, and other medical units. The services provided by the company include maternal care for expectant mothers, intensive care for premature babies, cardiology care for infants suffering from heart defects, and anesthesia care during surgeries, among others. The company operates only under one segment and generates majority of the revenue through neonatology and other pediatric subspecialties.
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Over the 3 months period, Pediatrix Medical Group showcased positive performance, achieving a revenue growth rate of 0.83% as of 31 March, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Pediatrix Medical Group's net margin excels beyond industry benchmarks, reaching 0.81%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Pediatrix Medical Group's ROE excels beyond industry benchmarks, reaching 0.47%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Pediatrix Medical Group's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.18% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Pediatrix Medical Group's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.91, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: MD